We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
-4.34%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$299M
AUM Growth
-$63.9M
Cap. Flow
-$54.5M
Cap. Flow %
-18.25%
Top 10 Hldgs %
28.29%
Holding
166
New
33
Increased
12
Reduced
17
Closed
48

Top Buys

Rank Stock Value
1
PEPLU
PepperLime Health Acquisition Corporation Unit
PEPLU
+$7.47M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$5.84M
3
DXCM icon
DexCom
DXCM
+$5.47M
4
KPTI icon
Karyopharm Therapeutics
KPTI
+$5.36M
5
IMGN
Immunogen Inc
IMGN
+$5.09M

Top Sells

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$8.71M
2
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
+$7.2M
3
IMTX icon
Immatics
IMTX
+$6.32M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$6.19M
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$5.62M

Sector Composition

Rank Sector Weight
1 Healthcare 78.49%
2 Financials 7.32%
3 Industrials 1.2%
4 Technology 0.83%
5 Communication Services 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
26
DELISTED
Immunogen Inc
IMGN
$4.38M 1.47%
+920,000
New +$5.09M
XTNT icon
27
Xtant Medical Holdings
XTNT
$61.8M
$4.25M 1.42%
6,246,291
– –
VSTM icon
28
Verastem
VSTM
$564M
$4.16M 1.39%
245,917
+58,167
+31% +$1M
INSP icon
29
Inspire Medical Systems
INSP
$1.73B
$4.11M 1.37%
16,000
-7,000
-30% -$1.6M
LIVN icon
30
LivaNova
LIVN
$4.14B
$4.09M 1.37%
+50,000
New +$3.89M
ISEE
31
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.97M 1.33%
236,000
-93,101
-28% -$1.38M
EUCR
32
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$3.94M 1.32%
400,000
– –
ILMN icon
33
Illumina
ILMN
$28.6B
$3.84M 1.29%
11,308
-6,682
-37% -$2.26M
POL.WS
34
DELISTED
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
$3.78M 1.26%
6,103,824
– –
EIGR
35
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.65M 1.22%
14,667
+5,967
+69% +$943K
OCUL icon
36
Ocular Therapeutix
OCUL
$2B
$3.44M 1.15%
695,000
– –
IMUX icon
37
Immunic
IMUX
$207M
$3.39M 1.13%
30,000
-1,700
-5% -$197K
ACET icon
38
Adicet Bio
ACET
$75.7M
$3.1M 1.04%
9,688
-6,750
-41% -$1.55M
MYGN icon
39
Myriad Genetics
MYGN
$309M
$2.89M 0.97%
114,710
-75,290
-40% -$1.93M
KRMD icon
40
KORU Medical Systems
KRMD
$166M
$2.85M 0.95%
995,500
– –
EYPT icon
41
EyePoint Inc
EYPT
$1.19B
$2.73M 0.91%
224,541
-459
-0.2% -$5.03K
KRTX
42
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$2.66M 0.89%
+21,000
New +$2.36M
TMPM
43
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$2.5M 0.84%
254,000
– –
MORF
44
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$2.41M 0.81%
60,000
– –
OM icon
45
Outset Medical
OM
$91.6M
$2.36M 0.79%
+3,467
New +$2.09M
HLMN icon
46
Hillman Solutions
HLMN
$1.78B
$2.33M 0.78%
196,000
+54,000
+38% +$531K
CLDX icon
47
Celldex Therapeutics
CLDX
$3.26B
$2.25M 0.75%
66,000
-60,000
-48% -$1.92M
SRSA
48
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
$2.23M 0.75%
225,000
– –
LNTH icon
49
Lantheus
LNTH
$6.59B
$2.21M 0.74%
40,000
-232,000
-85% -$8.71M
SLN
50
Silence Therapeutics
SLN
$558M
$2.07M 0.69%
+109,000
New +$2.17M
1
2
3 4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CF
Crosspoint Financial Tustin, California $39.8M AUM 14.13% 1-Year Est. Return

Altium Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Altium Capital Management held 166 positions worth $299M, down 18% from $363M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Altium Capital Management withdrew a net $54.5M in Q1 2022, closing 48 positions and reducing 17 holdings. Its most notable exit was PepperLime Health Acquisition Corporation Class A Ordinary Share, an estimated $7.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 80% a quarter earlier, followed by Financials and Industrials.

Against the trend, Altium Capital Management opened a new position in PepperLime Health Acquisition Corporation Unit worth $7.23M.

  • Altium Capital Management's largest Q1 2022 buy was PepperLime Health Acquisition Corporation Unit: 735,000 shares worth $7.23M.
  • Altium Capital Management added most to NEVRO CORP. in Q1 2022, an estimated $2.52M increase.
  • Altium Capital Management's biggest Q1 2022 reduction was Lantheus, cutting an estimated $8.71M.
  • Altium Capital Management fully exited PepperLime Health Acquisition Corporation Class A Ordinary Share in Q1 2022, selling an estimated $7.2M.
  • Altium Capital Management's ten largest holdings make up 28% of its $299M portfolio in Q1 2022.
  • Altium Capital Management opened 33 new positions and closed 48 in Q1 2022.
  • Altium Capital Management's portfolio value fell 18% quarter-over-quarter to $299M.

Based on Altium Capital Management's 13F filing for Q1 2022, filed 16 May 2022.